Abstract| Volume 19, ISSUE 5, SUPPLEMENT , S9, May 2017

Targeting leukemia using an inducible universal chimeric antigen receptor (UniCAR) T cell technology

      T cells genetically engineered to express chimeric antigen receptors (CARs) represent a promising approach in cancer immunotherapy. CARs consist of an extracellular binding moiety providing antigen specificity and an intracellular signaling domain derived from an activating immune receptor. Both are linked via a hinge and transmembrane domain. Introducing co-stimulatory domains, such as CD28 or CD137, can enhance signaling. Although, CAR T cells showed encouraging clinical results in patients with B cell malignancies, major drawbacks include on-target off-tumor effects or severe cytokine release syndrome (sCRS).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect